Quick Heal Technologies Ltd

- There is no mention of any current or planned fundraising through debt or equity in the provided transcript. - The company states it is a zero-debt company, indicating no outstanding debt on the balance sheet. - Management emphasizes a strong balance sheet and the ability to continue investing in R&D and sales and marketing without requiring external fund-raising. - No guidance or indication of plans to raise capital via equity issuance is provided in the earnings call.

- Quick Heal continues to invest heavily in research and development (R&D) as a form of capital investment, especially in new product development for enterprise and consumer segments. - FY '23 R&D expenses were ₹121 crore, with main components being manpower cost, technical collaboration charges, and cloud costs. - Future R&D expense is expected to be maintained at 25% to 30% of revenue, reflecting ongoing investment in product features and capabilities. - New products are planned for launch in H1 and H2 FY '24, with continuous feature additions to compete internationally. - Sales and marketing expenses are expected to stay similar next year with goals of substantially higher sales numbers. - No explicit mention of other capital expenditures besides R&D investments and sales/marketing costs. - The company emphasizes long-term investments despite short-term market challenges, maintaining a strong balance sheet and zero debt position.

- Enterprise segment has shown consistent growth with over 11 straight quarters of year-on-year increase. - Enterprise revenue surpassed 100 crore in FY '23, growing at over 20% CAGR in the last three years. - Expectation to cross 300 crore consolidated revenue mark in FY '24 with H2 marking revival after earlier slowdown. - Enterprise business projected to contribute at least 50% or more to total revenue in the next 4 to 6 quarters. - Continued investments planned in R&D and sales & marketing to support long-term growth. - New product launches in enterprise including endpoint protection, zero trust, and data privacy expected to deliver revenues from Q2 FY '24. - Consumer segment currently experiencing temporary contraction with anticipated bounce back from Q2 FY '24. - Market expansion planned into mid-sized enterprise and government segments with significant growth opportunities. - The company sees big potential to grow the enterprise business by expanding customer base and product range.

- The company does not provide specific guidance on revenue, costs, or earnings figures. (Navin Sharma, Page 7) - H2 FY '23 faced an unexpected slowdown, but FY '24 is expected to be a year of revival with revenues crossing Rs. 300 crore. (Navin Sharma, Page 7) - Enterprise segment has shown consistent growth with a 20% CAGR over the last three years and is expected to contribute at least 50% or more of total revenue in the next 4-6 quarters. (Sanjay Katkar, Page 7) - R&D expenses will remain significant, targeting 25-30% of revenue to sustain product innovation and expansion. (Kailash Katkar, Pages 8-9) - Sales and marketing costs are expected to remain stable or increase moderately to support new product launches and growth, especially in enterprise sales. (Navin Sharma, Page 11) - Cost optimization measures have been implemented, aiming to improve profitability gradually. (Navin Sharma, Page 4)

- The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies. - However, it notes that the Enterprise segment has been growing steadily with sustained quarter-on-quarter growth for nearly three years. - The company sees significant growth potential in the Enterprise business, especially in the SMB and mid-size corporate segments. - New product launches in Enterprise security (EDR, XDR, zero trust, data privacy) are expected to gain traction, with revenues anticipated from Q2 FY '24 onwards. - Management indicates ongoing efforts to onboard more customers and expects the Enterprise segment to contribute at least 50% of revenue in the next 4-6 quarters. - No concrete figures for order backlog or pending orders were disclosed during the call.